It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

1 Study Protocol

Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study.

Santos-García D^{1,2,3,4}, González-Ortega G⁵, Sánchez Alonso P⁶, Planas-Ballvé A⁷, García
Ramos R⁸, Cabo López I⁹, Blázquez Estrada M¹⁰, Sánchez Ferro A^{11,12}; DATs-PD GETM
Spanish Registry Group (Appendix 1).

¹CHUAC, Compleio Hospitalario Universitario de A Coruña, A Coruña, Spain, ²Grupo de 7 Investigación en Enfermedad de Parkinson y otros Trastornos del Movimiento, INIBIC (Instituto 8 9 de Investigación Biomédica de A Coruña). A Coruña. Spain, ³Hospital San Rafael, A Coruña. ⁴Fundación Degen, A Coruña, Spain. ⁵Hospital Universitario de Móstoles, Madrid, Spain. 10 ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain. ⁷Complex Hospitalari Moisès Broggi, 11 Sant Joan Despí, Llobregat, Barcelona, Spain. 8Hospital Universitario Clínico San Carlos, 12 13 Madrid, Spain. ⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain. ¹⁰Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain. ¹¹Hospital Universitario 12 14 de Octubre, Madrid, Spain. ¹²Centro de Investigación Biomédica en Red sobre Enfermedades 15 Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Medicine, Universidad 16 Complutense, Madrid, Spain 17

18

19 Word count: abstract 250; text, 2,591 (without references). Tables: 1. Figures: 1.

20 Supplementary Material: None.

21 **Running title:** Device-aided therapies in Parkinson's disease.

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

22 Keywords: Device-aided therapies; Deep Brain stimulation; Infusion; Parkinson's disease;

23 Registry.

24 *Corresponding author:

- 25 Dr. Diego Santos García, Department of Neurology, Hospital Universitario de A Coruña (HUAC),
- 26 Complejo Hospitalario Universitario de A Coruña (CHUAC), C/ As Xubias 84, 15006, A Coruña,
- 27 Spain; e-mail: diegosangar@yahoo.es; Tel: + 34 646173341.

28

Abbreviations: ADL, activities of daily living; CSAI, continuous subcutaneous apomorphine infusion; DATs, device-aided therapies; DBS, deep brain stimulation; fLD/fCD, foslevodopafoscarbidopa; LCIG, levodopa-carbidopa intestinal gel infusion; LECIG, levodopa-entacaponecarbidopa intestinal gel infusion; LEED, levodopa equivalent daily dose; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale.

- 34
- 35
- 36
- 37
- 38
- 39
- -
- 40

- 42
- 43

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

44 ABSTRACT

Background and objective: Device-aided therapies (DATs) are treatments indicated for people 45 with Parkinson's disease (PwP) with clinical fluctuations that are not optimally controlled with 46 conventional medication. New DATs have recently emerged such as levodopa-entacapone-47 carbidopa intestinal ael infusion (LECIG) and subcutaneous infusion of 48 foslevodopa/foscarbidopa (fLD/fCD). It is necessary to know the differences between different 49 DATs. 50

Patients and Methods: We present here the protocol study of the DATs-PD GETM Spanish 51 52 Registry. This is a descriptive, observational, prospective, multicenter, open study that is proposed as a clinical registry with progressive inclusion of PwP treated with a DAT in daily 53 clinical practice conditions in more 40 centers from Spain for 10 years. The principal aim is to 54 know the type of DAT that PwP in our country (Spain) receive. Specific objectives are to 55 compare the clinical characteristics of the patients, the effectiveness, safety and tolerability, to 56 identify predictors of a good response and to analyze the response by groups (gender, disease 57 duration, phenotype, etc.). There is a baseline visit (V1; indication of the therapy), start visit (V2; 58 initiation of the therapy) and follow-up visits at 6 months \pm 3 months (V3 6M) and after this 59 annually ± 3 months (V3 12M, V3 24M, etc.). 60

Results: The registry is on-going. The first patient was included on Abril 10, 2024. Patient recruitment and follow-up will be conducted until 31/DEC/2033. The estimate is to reach a minimum sample size of at least 3,000 patients.

64 **Conclusion:** The present study will help improve the care of PD patients treated with a DAT.

65

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

66 Authors' Roles:

Santos-García D: conception, organization, and execution of the project: funding acquisition: 67 supervision; writing of the first draft of the manuscript; recruitment and/or evaluation of 68 participants; entering data into the database. González-Ortega G: preparation and 69 70 development of the database: registration of participants in the platform; recruitment and/or evaluation of participants: entering data into the database: review and critique. Sánchez 71 Alonso P: recruitment and/or evaluation of participants: entering data into the database; review 72 and critique. Planas-Ballvé A: recruitment and/or evaluation of participants: entering data into 73 74 the database: review and critique. García Ramos R: recruitment and/or evaluation of participants: entering data into the database: review and critique. Cabo López I: recruitment 75 and/or evaluation of participants; entering data into the database; review and critique. Blázquez 76 **Estrada** M: recruitment and/or evaluation of participants; entering data into the database; 77 review and critique. Sánchez Ferro A: collaboration in the coordination of the project as 78 coordinator of GETM: recruitment and/or evaluation of participants; entering data into the 79 database; review and critique. 80

81

82 Financial Disclosures for the previous 12 months:

Santos-García D. has received honoraria for educational presentations and advice service by
Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve,
Stada, Merz, and grants from the "Fundación Professor Novoa Santos" as a result of the
"CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE
INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)".

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

- **González-Ortega** G. has received honoraria for educational purposes from ABBIE, Zambon,
- 89 Bial, Esteve and Italfarmaco
- 90 Sánchez Alonso P. has received honoraria for educational presentations and advice service by
- 91 Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva.
- 92 Planas-Ballvé A: None.
- García Ramos R. has received honoraria and grants for lecturing, advisory services from
 Abbvie, Zambón, Bial, Merk, Stada.

Cabo López I. has received honoraria for educational presentations and advice service by
 Abbvie, Zambon, Bial, Orion, Italfarmaco and Esteve.

- 97 Blázquez Estrada M. has received honoraria for educational presentations by Dysport, Esteve,
- ⁹⁸ Bial, Italfármaco, Boston Sc. and Stada and for advice service by Esteve, Bial, Suazio.

Sánchez Ferro A. has received: grants or contracts from ERA-NET Horizon 2020 program JPCOFUND2 (reference number HESOCARE-329-073), MDS (eDiary project), Instituto de Salud Carlos III (reference number P122/01177); consulting fees from Abbvie, Esteve, Orion Pharma, and Prim; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Bayer, Esteve, MDS Society, EAN, Novartis, Monitor, Organon, Roche, SEN, Stada, Teva, and Zambon,

- 104
- 105
- 106
- 107
- 108
- 109

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

110 INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disease after 111 Alzheimer's disease. It is characterized by a deficit of dopamine in the striatum and other brain 112 areas, but also of other neurotransmitters such as noradrenaline, acetylcholine or serotonin, 113 which would explain the appearance of motor and non-motor symptoms characteristic of the 114 disease [1]. The diagnosis is made by applying well-defined criteria [2,3] that are based 115 fundamentally on the existence of parkinsonism, the absence of atypical data that suggest an 116 alternative diagnosis (pharmacological, Parkinson-Plus syndrome, etc.), and data in favor that 117 118 suggest PD itself. Among the latter, a determining aspect is the good response to dopaminergic medication, especially levodopa [4]. Its administration compensates for the deficit of 119 dopaminergic stimulation at the level of the postsynaptic receptors, which causes an 120 improvement in symptoms such as tremor, rigidity or bradykinesia, among others. In fact, the 121 absence of a response would go against the diagnosis of PD. 122

Although the response to dopamineraic medication may be optimal during the first few 123 years, people with PD (PwP) develop motor and non-motor complications (e.g., motor 124 fluctuations, non-motor fluctuations, dyskinesias, etc.) that impact their quality of life and 125 autonomy [5]. Thus, PwP may only perceive improvement at certain times of the day alternating 126 with disabling OFF episodes where the symptoms reemerge and the control with conventional 127 medication is insufficient [6]. Some PwP may benefit from treatment with a second-line therapy 128 129 that is an alternative and/or complement to conventional medication that is not sufficient [7]. The proper selection of the candidates is key, and there are different tools for their correct 130 131 identification [8]. These therapies are commonly known as device-aided therapies (DATs) and

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

132 although they are more expensive and complex than conventional medication, they have been shown to reduce OFF time, improve non-motor symptoms and the quality of life of PwP [9]. For 133 many years the available DATs in many countries have been the deep brain stimulation (DBS). 134 continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel 135 infusion (LCIG) [10]. However, new treatments have recently emerged, such as levodopa-136 entapacone-carbidopa intestinal gel infusion (LECIG) and subcutaneous infusion of 137 foslevodopa-foscarbidopa (fLD/fCD) [11,12]. Particularly relevant is the recent availability of 138 fLD/fCD subcutaneous infusion to the point that many recently published treatment algorithms 139 140 are outdated and the possibility of considering the subcutaneous route as the first alternative to the enteral route is being discussed, as it is less invasive when considering infusion therapy 141 [13,14]. 142

Therefore, a completely new scenario is opening up in the treatment of PwP with a DAT 143 and it is essential to know the frequency of the prescriptions, the characteristics of the treated 144 145 individuals as well as their long-term evolution in relation to clinical changes and complications. This is the reason why, from the Movement Disorders Study Group (Grupo de Estudio de 146 Trastornos de Movimiento [GETM]) of the Spanish Neurological Society (Sociedad Española de 147 Neurología [SEN]), we have launched a prospective registry of PwP treated with a DAT in our 148 country (Spain). The aim of this article is to describe this registry that we have named DATs-PD 149 GETM Spanish Registry. 150

151

152 METHODS/DESIGN

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

Title of the Project: Device-aided therapies in Parkinson's disease GETM Spanish Registry
 (DATs-PD GETM Spanish Registry).

Type of study: Descriptive, observational, prospective, multicenter, open study that is proposed as a clinical registry with progressive inclusion of patients with PwP treated with a DAT in daily clinical practice conditions.

158 **Promoter and principal coordinator of the project:** Diego Santos García, MD, PhD.

159 **Coordinating institutions:** "Fundación Degen", "Grupo de Estudio de Trastornos del 160 Movimiento (GETM)" and "Sociedad Española de Neurología (SEN)".

Participating centers in the project: More than 40 centers from Spain with neurology teams
 with experience in the management of PD (Appendix 1), including the use of DATs.

Population: PwP treated with a DAT in Spain from year 2024. The following therapies are included as DATs: DBS; CSAI; LCIG; LECIG; and fLD/fCD subcutaneous infusion. In addition, PwP who are treated with focused ultrasound-guided thermal ablation will also be included. Specifically, the eligibility criteria are: 1) diagnosis of PD according to the MDS criteria; 2) start of treatment with a DAT from January 1, 2024; 3) the patient's desire to participate on a completely voluntary basis; 4) signing of an informed consent.

Justification of the project: 1) there are many DATs currently used to treat PwP; 2) some of them have been introduced very recently and we have no experience; 3) in this context, we must know about the indication preferences in Spanish centers that treat PwP; 4) we must know the characteristics of the individuals treated and the differences between therapies; 4) we must know the effectiveness of DATs and to compare them; 5) we must know the safety and

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

tolerability of DATs and to compare them; 6) it is necessary to define different response profiles
or predictors of better or worse outcome; 7) this is an excellent opportunity to be able to develop
a registry at this time that collects a lot of information over the long term; 8) It could be a starting
point to which centers from other countries can join and develop a broader registry (e.g.,
European, etc.).

179 **Objectives**

Principal objective: to know the type of DAT that PwP in our country receive, treated by expert
 neurologists in daily clinical practice conditions.

Specific objectives: 1) to analyze the sociodemographic and clinical characteristics of PwP 182 treated with a DAT, comparing the different treatments (DBS vs subcutaneous vs enteral 183 184 treatment): 2) to analyze the effectiveness of different DATs, comparing the different treatments 185 (DBS vs subcutaneous vs enteral treatment); 3) to analyze the safety and tolerability of different DATs, comparing the different treatments; 4) specifically, to analyze the changes experienced 186 by PwP treated with DATs in the perception of their guality of life and autonomy for carrying out 187 daily activities and to compare the different treatments; 5) specifically, to compare the rate of 188 189 maintenance of the therapy between the different DAT groups; 6) specifically, to compare the dropout rate for each of the therapies and find out the underlying reasons; 7) to find out the 190 reasons for changing from one therapy to another or adding a second DAT to a previous one 191 being received; 8) to analyze the complications in relation to the different DATs and compare 192 193 them; 9) to compare the differences by gender (male vs. female); 10) others that may be raised based on the data collected (e.g., differences by age, disease duration etc.). 194

195 Visits

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

The registry includes 3 types of visits: 1) baseline visit (V1), which is when the DAT is decided by the neurologist; 2) start visit (V3), which is when the DAT is initiated by the patient; 3) followup visit (V3), with the patient receiving the DAT. The first follow-up visit will be carried out at 6 months +/- 3 months (V3_6M) and then at 1 year +/-3 months and subsequently annually +/- 3 months: 1 year (V3_12M); 2 years (V3_24M); 3 years (V3_36M); 4 years (V3_48M); 5 years (V3_60M); etc. (**Figure 1**).

The period of inclusion of patients in the registry will be a minimum of 5 years, extendable to 10 202 vears according to the approved protocol. New PwP will be included over a 10-year period. 203 204 while each participant's included will be follow-up during this time. The data collection period ranges from January 1, 2024 to December 31, 2033. If a person with PD switches to another 205 DAT or a second DAT is added, the information will be collected. In addition, if a subject drops 206 out of the DAT and does not receive another DAT, data collection will continue within the 207 registry to allow for a comparative arm of untreated patients after a therapeutic failure 208 (something rarely discussed in the literature). Although the registry is prospective, it is planned 209 to include PwP treated in 2024 whose indication for DAT was before this year, as long as the 210 data was properly collected in the medical record. An example is DBS, given that the waiting list 211 from indication to intervention is long in some centers. 212

213 Assessments

The following information will be collected at each visit:

1) Baseline visit (V1): sociodemographic data; data about PD (age onset, disease duration,

216 motor phenotype, etc.); comorbidities; treatments; main reason for therapy indication; 217 levodopa equivalent daily dose (LEDD) [15]; motor symptoms; non-motor symptoms;

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

218	Unified Parkinson's Disease Rating Scale (UPDRS-III) [16] during the OFF state;
219	UPDRS-III during the ON state; Hoehn & Yahr (H&Y) [17] stage in OFF; H&Y stage in
220	ON; MNCD classification (classification; score; stage) [18]; Parkinson's Disease
221	Questionnaire (PDQ-39) [19]; EUROHIS-QOL 8-item index [20]; Schwab and England
222	Activities of Daily Living Scale (ADLS) [21] during the OFF and during the ON state;
223	serum levels of folate, B vitamins (B1, B6, B12) and homocysteine.

224 2) Start visit (V2): data about the DAT and treatment settings including LEDD.

3) Follow-up visit (V3): data about the DAT and treatment settings including LEDD;
comorbidities; treatments; LEDD; motor symptoms; non-motor symptoms; UPDRS-III
during the ON state; H&Y stage in ON; MNCD classification (classification; score; stage);
Parkinson's Disease Questionnaire (PDQ-39); EUROHIS-QOL 8-item index; ADLS
during the OFF and during the ON state; serum levels of folate, B vitamins (B1, B6, B12)
and homocysteine; complications about the DAT and/or other relevant complications.

All information will be collected by expert neurologists in a daily clinical practice setting. A total of 16 and 26 questions collect information on motor symptoms/complications and nonmotor symptoms, respectively, which are categorized as absent, mild, moderate, severe, or very severe. The score on the MDS-UPDRS-III scale [22] will be an added option that will be collected in those centers that use it (permission by the MDS was obtained). **Table 1** summarizes the information on the variables that will be collected during the different visits.

237

7 Data collection and statistical analysis

Data will be collected using REDCap. This is a secure web application for building and managing online surveys and databases. REDCap has been used to date (27/NOV/2024) in

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

240 159 countries by more than 3.4 million users. Data collected will be transferred to a statistical package for subsequent analysis. The promoter team of the project will be responsible for study 241 monitoring. The estimate, with the participation of more than 40 centers and a recruitment 242 period of 10 years, is to be able to reach a minimum sample size of 3,000 patients. The 243 pertinent analysis (descriptive, missing data analysis, normality assumptions, univariate, binary 244 logistic regression, multiple linear regression, etc.) will be performed based on the type of 245 objective. In addition, given de complexity of potential analysis including a diversity of variables 246 from different origin and measurement properties, advanced statistical methodology (data 247 248 mining, machine learning or other artificial intelligence techniques, etc.) could be considered when applicable. 249

250 Standard protocol approvals, registrations, and patient consents

The project will be conducted in accordance with the ICH Good Clinical Practice version 6 Revision 2 standard, the fundamental ethical principles established in the Declaration of Helsinki and the Oviedo Convention, as well as the Spanish legal requirements for biomedical research (Biomedical Research Law 14/2007). The Project has been approved on 02/APR/2024 by the IRB "Comité de Ética de la Investigación Clínica de Galicia from Spain" with code number 2024/109. Written informed consents from all participants in this study will be obtained.

257 Data availability

The protocol, statistical analysis plan and deidentified participant data will be available on request.

260 Study timetable

1) Pre-start-up procedures: until April 2024.

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

- 262 2) First patient included: 10/APR/2024.
- 3) First analysis to present: 2025 Q1 (data about PD patients treated in 2024).
- 4) Proposed specific objectives and others: from 2025 onwards.

265 **Funding statement**

An amount of 25.000 euros has been granted by the "Fundación Professor Novoa Santos" as a result of the "CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)". The import will be used for data monitoring and other actions required in the context of the project.

271 Strengths and limitations of the project

The main strength of the project is the possibility of collecting systematic information on patients 272 273 treated with DATs over a long follow up period (10 years). Further, there is great interest in the 274 fact that some of these therapies are novel and the management of advanced PD patients is 275 changing because of this and could hence be evaluated. Also, the methodology with prospective follow-up and the collection of well-defined variables (UPDRS, H&Y, PDQ-39, 276 ADLS, etc.) in a clinical practice setting will allow generalizing the findings to other 277 environments. To this end, we also consider in the future increasing the number of centers in 278 279 Spain, and even the chance of extrapolating the registry to other countries harmonizing the data collected. Other future possibilities are implementing new technologies to monitor the disease 280 and analyze the changes after starting with the DAT and their correlation with the data collected 281 282 from the registry.

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

On the other hand and as limitations, unlike a study with a clearly defined protocol in which multiple scales are administered [23], this project is a registry, and limitations in the quantity and quality of the data collected are possible. For example, the number and description of complications may be underestimated. At this moment the project is exciting but there is some residual risk that it will not work properly due to the workload of researchers.

288

289 DISCUSSION

According to the PARADISE study, a non-interventional, cross-sectional, multicenter, 290 291 national study conducted in the hospital setting and published in 2021, up to 38.2% of people with PD in Spain have advanced PD [24]. The key aspect of identifying advanced PD is to 292 differentiate which PwP could be candidates to receive a DAT. However, only 15.2% of PwP 293 from the advanced PD group from the PARADISE study were receiving some form of therapy 294 for advanced stages of the disease (i.e., DBS, CSAI, LCIG). The most frequent reasons why 295 advanced PwP were not on a DAT were "to be clinically stable" and "option not vet considered". 296 Similar results were observed in the PROSPECT study [25], in which only 20.9% of PwP (adults 297 with levodopa-responsive PD and inadequately controlled motor symptoms with \geq 2.5-hours/day 298 "Off" time, despite trials of available oral/transdermal/sublingual/inhalable medication) initiated a 299 DAT despite the fact that, as expected, DAT vs best medical therapy improved motor 300 symptoms, non-motor symptoms, sleep, guality of life, independence for ADL and caregiver 301 burden. For many years, the options for being treated with a DAT meant choosing between 302 three alternatives: DBS, CSAI, LCIG. However, the scenario is new with the current availability 303 304 of LECIG and subcutaneous fLD/fCD. In particular, it is of maximum interest to know whether

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

305 the arrival of fLD/fCD implies a reduction in the indication of other treatments and what are the characteristics of the treated patients as well as their complications in comparison with other 306 307 DATs, especially enteral therapies [26]. This registry aims to answer this question and many others explained in the objectives. We believe that the information collected in the DATs-PD 308 GETM Spanish Registry will be of great interest in helping to improve the management of 309 people with Parkinson's disease treated with a DAT. 310 In summary, we present here the protocol study of the DATs-PD GETM Spanish 311 Registry, a descriptive, observational, prospective, multicenter, open study that is proposed as a 312

clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more 40 centers from Spain for 10 years. The present study will help improve the care of PwP treated with a DAT.

- 316
- 210
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

327 **Table 1.** Variables collected in the DAT-PD Spanish Registry according to the type of visit.

Sociodemographic PD historyInformation about DAT Concomitant treatments LEDDInformation about DAT Concomitant treatments LEDDConcomitant treatments LEDDEDDPD symptoms Motor symptoms Non-motor symptomsMotor symptoms Motor scalesWotor symptoms UPDRS-III-OFF UPDRS-III-OFF UPDRS-III ON H&Y-OFF EUROHIS-QOL8WDRS-III-OFF H&Y-ON Quality of life PDQ-39 EUROHIS-QOL8Functional dependency ADLS-OFF ADLS-OFF ADLS-OFFFolate Vitamin B1 Vitamin B1Folate Vitamin B1Vitamin B1 Vitamin B1OrOr	V1	V2	V3
PD historyConcomitant treatmentsConcomitant treatmentsComorbiditiesLEDDPD symptomsConcomitant treatmentsLEDDLEDDPD symptomsMain reason for DATNon-motor symptomsPD symptomsMotor symptomsMotor symptomsUPDRS-III-OFFUPDRS-III-OFFUPDRS-III ONUPDRS-III OFFH&Y-ONUPDRS-III ONH&Y-OFFH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Functional dependencySerum biomarkersADLS-OFFVitamin B1Vitamin B1Vitamin B1Vitamin B1UptomationVitamin B2UptomationVita	Sociodemographic	Information about DAT	Information about DAT
ComorbiditiesLEDDLEDDConcomitant treatmentsPD symptomsMotor symptomsLEDDMain reason for DATPD symptomsPD symptomsMotor symptomsMotor symptomsMotor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III OFFUPDRS-III ONUPDRS-III ONH&Y-ONUPDRS-III ONEUROHIS-QOL8Quality of lifePDQ-39PDQ-39EUROHIS-QOL8Functional dependencySerum biomarkersADLS-OFFVitamin B1Vitamin B1Vitamin B1Vitamin B1Homocysteine	PD history	Concomitant treatments	Concomitant treatments
Concomitant treatmentsPD symptomsLEDDMotor symptomsMain reason for DATNon-motor symptomsPD symptomsMotor scalesMotor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFolateVitamin B1Vitamin B1Homocysteine	Comorbidities	LEDD	LEDD
LEDDMotor symptomsMain reason for DATNon-motor symptomsPD symptomsMotor scalesMotor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFolateVitamin B1Vitamin B1Homocysteine	Concomitant treatments		PD symptoms
Main reason for DATNon-motor symptomsPD symptomsMotor scalesMotor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFunctional dependencySerum biomarkersADLS-OFFVitamin B1Vitamin B1Uitamin B12Vitamin B1Homocysteine	LEDD		Motor symptoms
PD symptomsMotor scalesMotor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFunctional dependencySerum biomarkersADLS-OFFVitamin B1Vitamin B1Uitamin B12Vitamin B1Homocysteine	Main reason for DAT		Non-motor symptoms
Motor symptomsUPDRS-III-OFFNon-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFunctional dependencySerum biomarkersADLS-OFFVitamin B1Vitamin B1Vitamin B12Vitamin B1Homocysteine	PD symptoms		Motor scales
Non-motor symptomsUPDRS-III ONMotor scalesH&Y-OFFUPDRS-III-OFFH&Y-ONUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFunctional dependencySerum biomarkersADLS-OFFVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	Motor symptoms		UPDRS-III-OFF
Motor scalesH&Y-OFFUPDRS-III-OFFUPDRS-III ONUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8Serum biomarkersFunctional dependencySerum biomarkersADLS-OFFVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	Non-motor symptoms		UPDRS-III ON
UPDRS-III-OFFH&Y-ONUPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	Motor scales		H&Y-OFF
UPDRS-III ONQuality of lifeH&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	UPDRS-III-OFF		H&Y-ON
H&Y-OFFPDQ-39H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-OFFVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	UPDRS-III ON		Quality of life
H&Y-ONEUROHIS-QOL8Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	H&Y-OFF		PDQ-39
Quality of lifeFunctional dependencyPDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	H&Y-ON		EUROHIS-QOL8
PDQ-39ADLS-OFFEUROHIS-QOL8ADLS-ONFunctional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	Quality of life		Functional dependency
EUROHIS-QOL8ADLS-ONFunctional dependency ADLS-OFFSerum biomarkers FolateADLS-ONVitamin B1Serum biomarkers FolateVitamin B6 Vitamin B12Vitamin B1Homocysteine	PDQ-39		ADLS-OFF
Functional dependencySerum biomarkersADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	EUROHIS-QOL8		ADLS-ON
ADLS-OFFFolateADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	Functional dependency		Serum biomarkers
ADLS-ONVitamin B1Serum biomarkersVitamin B6FolateVitamin B12Vitamin B1Homocysteine	ADLS-OFF		Folate
Serum biomarkers Vitamin B6 Folate Vitamin B12 Vitamin B1 Homocysteine	ADLS-ON		Vitamin B1
Vitamin B1 Vitamin B2	Serum biomarkers		Vitamin B6
Vitamin B1 Homocysteine	Folate		Vitamin B12
	Vitamin B1		Homocysteine
Vitamin Bo Complications	Vitamin B6		Complications
Vitamin B12 Related with DAT	Vitamin B12		Related with DAT
Homocysteine Unrelated with DAT	Homocysteine		Unrelated with DAT

³²⁸

daily dose; PD, Parkinson's disease; PDQ-39, the 39-item Parkinson's disease Questionnaire; UPDRS, Unified

331 Parkinson's Disease Rating Scale.

332

³²⁹ ADLS, Schwab & England Activities of Daily Living Scale; DAT, device-aided therapy; LEDD, levodopa equivalent

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

340 **References**

- 1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397:2284-303.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic
 Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg
 Psychiatry 1992;55;181-4.
- 345 3. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical 346 diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591-601.
- 347 4. Santos-García D, de us Fonticoba T, Cores Bartolomé C, et al.; COPPADIS Study Group.

Response to levodopa in Parkinson's disease over time. A 4-year follow-up study. Parkinsonism Relat Disord 2023;116:105852.

- 5. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor
 fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-60.
- 352 6. Kakimoto A, Kawazoe M, Kurihara K, Mishima T, Tsuboi Y. Impact of non-motor fluctuations
- on QOL in patients with Parkinson's disease. Front Neurol 2023;14:1149615.

Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder
 Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive
 Therapies. Mov Disord 2022;37:1360-74.

- Moes HR, Henriksen T, Sławek J, Phokaewvarangkul O, Buskens E, van Laar T. Tools and
 criteria to select patients with advanced Parkinson's disease for device-aided therapies: a
 narrative review. J Neural Transm (Vienna) 2023;130:1359-77.
- 360 9. Phokaewvarangkul O, Auffret M, Groppa S, Markovic V, Petrovic I, Bhidayasiri R. What was

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

361	first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing
362	evidence and experience. J Neural Transm (Vienna) 2024;131:1307-20.
363	10. Auffret M, Weiss D, Stocchi F, Vérin M, Jost WH. Access to device-aided therapies in
364	advanced Parkinson's disease: navigating clinician biases, patient preference, and
365	prognostic uncertainty. J Neural Transm (Vienna) 2023;130:1411-32.
366	11. Santos-García D, López-Manzanares L, Muro I, at el. Effectiveness and safety of levodopa-
367	entacapone-carbidopa infusion in Parkinson disease: A real-world data study. Eur J Neurol
368	2024 (epub ahead of print).
369	12. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous
370	foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised,
371	double-blind, active-controlled, phase 3 trial. Lancet Neurol 2022;21(12):1099-109.
372	13. Antonini A, D'Onofrio V, Guerra A. Current and novel infusion therapies for patients with
373	Parkinson's disease. J Neural Transm (Vienna) 2023;130:1349-58.
374	14. Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's
375	Disease: A Mini-Review of Current Scope and Future Outlook. Mov Disord Clin Pract
376	2024;11:1188-94.
377	15. Nyholm D, Jost WH. An updated calculator for determining levodopa-equivalent dose.
378	Neurol Res Pract 2021;3:58.
379	16. Fanhn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's
380	Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent
381	developments in Parkinson's disease, Vol 2. Florham Park, NJ: Macmillan Health Care

It is made available under a CC-BY 4.0 International license .

- 382 Information;1987.p-153-64.
- 17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology
 1967:17:427-42.
- 18. Santos García D, Álvarez Sauco M, Calopa M, et al. MNCD: A New Tool for Classifying
 Parkinson's Disease in Daily Clinical Practice. Diagnostics (Basel) 2021:12:55.
- 19. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease
 Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary
 index score. Age Ageing 1997;26:353-7.
- 20. Da Rocha NS, Power MJ, Bushnell DM, Fleck MP. The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health 2012;15:449-57.
- 21. Schwab RS, England AC. In Third Symposium on Parkinson's disease. E. And S.
 Livingstone: Edinburgh 1969;152-7.
- 22. Goetz CG, Tilley BC, Shaftman SR, et al.; Movement Disorder Society UPDRS Revision
 Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's
 Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov
 Disord 2008;23:2129-70.
- 23. Santos-García D, Mir P, Cubo E, Vela L, et al.; COPPADIS Study Group. COPPADIS-2015
 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations,
 serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non interventional, long-term study on Parkinson's disease progression. BMC Neurol

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

403 2016;16:26.

- 404 24. Martínez-Castrillo JC, Martínez-Martín P, Burgos Á, et al. Prevalence of Advanced
 405 Parkinson's Disease in Patients Treated in the Hospitals of the Spanish National Healthcare
 406 System: The PARADISE Study. Brain Sci 2021;11(12):1557.
- 407 25. Dean MN, Standaert DG. Levodopa infusion therapies for Parkinson disease. Curr Opin
 408 Neurol 2024;37:409-413.
- 409 26. de Fabregues O, Falconer D, Heshmat S, et al. Long-Term Evolution of Advanced
 410 Parkinson's Disease Burden: Subgroup Analysis from the 24 Month International
 411 PROSPECT Observational Study [abstract]. Mov Disord 2024;39(suppl 1).

It is made available under a CC-BY 4.0 International license.

Device-aided therapies in Parkinson's disease

425 Legend of Figures

Figure 1. All patients treated with a DAT from 2024 to 31/DEC/2033 in more than 40 participating centers from Spain are included, all of them evaluated by neurologists who are experts in PD. Each color refers to a different patient. There is a baseline visit (V1; indication of the therapy), start visit (V2; initiation of the therapy) and follow-up visits at 6 months (V3_6M) and after this annually (V3_12M, V3_24M, etc.). The window for V2 and V3 is ± 3 months.

431

432 Acknowledgements

433 We would like to thank all patients who collaborated in this study. Many thanks also to Fundación Española de Avuda a la Investigación en Enfermedades Neurodegenerativas v/o de 434 Origen Genético (https://fundaciondegen.org/), Grupo de Estudio de Trastornos del Movimiento 435 (GETM), Sociedad Española de Neurología (SEN) and Fundación Profesor Novoa Santos. 436 437 438 439 440 441 442 443 444

445

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

447 Appendix 1.

448 DATS-PD GETM Spanish Registry STUDY GROUP

Adarmes Gómez AD, Alonso Modino D, Álvarez Sauco M, Aneiros Díaz A, Ávila Rivera A, 449 Baviera-Muñoz R, Belmonte S, Blázquez Estrada M, Caballero Sánchez L, Caballol Pons N, 450 Cabo López I. Campins Romey M. Campolongo A. Cantarero Duque S. Carrillo García F. 451 Casanova Mollá J. Casas Peña E. Castaño García B. Castellano Guerrero AM. Castrillo Sanz 452 A, Cerdán Santacruz DM, Clavero Ibarra P, Cores Bartolomé C, Cots Foraster A, Cubo Delgado 453 E. Delgado Ballestero T. Erdocia Goñi A. Escalante Arrovo S. Escamilla Sevilla F. Espinosa 454 Rosso R., Faniul Arbos S., Feliz Feliz C., Fernández Pajarín G., Fernández Revuelta A. 455 Fernández Rodríguez B. Fernández Valle T. Freire Álvarez E. Gamo González E. García 456 457 Fernández C, García Herruzo A, García Ramos García R, García Ruíz Espiga P, Garrote Espina L, Gil Villar MP, Gómez Esteban JC, Gómez López de San Román C, Gómez 458 Mayordomo V, Gómez Rapela C, González MV, González Ardura J, González Hernández A, 459 González-Ortega G. Guerra Hiraldo JD. Gutiérrez García J. Hernández Vara J. Jesús Maestre 460 S, Kulisevsky Bojarski J, Legarda Ramírez I, López Ariztegui N, López Dominguez D, López 461 Manzanares L, López Veloso AC, López Valdés E, Lorenzo Barreto P, Lorenzo Brito JM, 462 Lozano D. Macías García D. Madrid Navarro CJ. Martí Andrés G. Martí Martínez S. Martín 463 García R. Martínez Castrillo JC. Martínez-Torres I. Mata Álvarez Santullano M. Mauri Fabrega 464 L, Méndez Guerrero A, Mendoza Rodríguez A, Mir Rivera P, Mondragón Rezola E, Monterde 465 466 Ortega A, Morales Casado MI, Morata-Martínez C, Muñoz Delgado L, Muñoz Ruíz T, Muro I, Novo Ponte S, Ojeda Lepe E, Olivares Romero J, Pagonabarraga J, Pareés Moreno I, Pascual 467 Sedano B, Paz González JM, Peral Quirós A, Pérez Calvo C, Pérez Rangel D, Perona 468

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

469	Moratalla A, Planas-Ballvé A, Prendes Fernández P, Quibus Requena L, Rábano Suárez P,
470	Rashid López R, Rebollo Lavado B, Rojas Pérez E, Ribacoba Díaz C, Romero Fábrega JC,
471	Ruiz López M, Ruíz Martínez J, Samaniego Vinueza LB, San Eufrasio Martínez M, Sánchez
472	Alonso P, Sánchez Ferro A, Sánchez Rodríguez A, Sancho Saldana A, Santos-García D,
473	Sastre Bataller I, Sesar Ignacio A, Solano Vila B, Solleiro Vidal A, Suárez San Martín E, Tabar
474	Comellas G, Tijero Merino B, Triguero Cueva L, Valero García MF, Valldeoriola Serra F, Vela L,
475	Vinagre Aragón A, Vivas Villacampa L, Vives Pastor B, Yáñez Baña R.

First Name	Last Name	Centre
Diego	Santos García	Complejo Hospitalario Universitario de A Coruña
Jose Manuel	Paz González	Complejo Hospitalario Universitario de A Coruña
Carlos	Cores Bartolomé	Complejo Hospitalario Universitario de A Coruña
Lucia Belen	Samaniego Vinueza	Complejo Hospitalario Universitario de A Coruña
Ángela	Solleiro Vidal***	Complejo Hospitalario Universitario de A Coruña
María	Álvarez Sauco	Hospital General Universitario de Elche
Eric	Freire Álvarez	Hospital General Universitario de Elche
Juan Carlos	Martínez Castrillo	Hospital Universitario Ramón y Cajal
Isabel	Pareés Moreno	Hospital Universitario Ramón y Cajal
Samira	Fanjul Arbos	Hospital Universitario Ramón y Cajal
Ana Belén	Perona Moratalla	Complejo Hospitalario Universitario de Albacete
Inés	Legarda Ramírez	Hospital Universitario Son Espases
Bàrbara	Vives Pastor	Hospital Universitario Son Espases
María Fuensanta	Valero García	Hospital Universitario Son Espases
Esther	Cubo Delgado	Hospital Universitario de Burgos
Nuria	López Ariztegui	Hospital Universitario de Toledo
Maria Isabel	Morales Casado	Hospital Universitario de Toledo
Guillermo	Tabar Comellas	Hospital Universitario de Toledo
Déborah	Alonso Modino	Hospital Universitario de la Candelaria
Jesús Norelis	Lorenzo Brito	Hospital Universitario de la Candelaria
Esther	Rojas Pérez	Hospital Universitario de la Candelaria
Iria	Cabo López	Complejo Hospitalario Universitario de Pontevedra

It is made available under a CC-BY 4.0 International license .

Jorge	Hernández Vara	Hospital Universitario Vall d'Hebron
Maria Victoria	González	Hospital Universitario Vall d'Hebron
Sara	Belmonte**	Hospital Universitario Vall d'Hebron
Juan Carlos	Romero Fábrega	Hospital Universitario Virgen de las Nieves
Francisco	Escamilla Sevilla	Hospital Universitario Virgen de las Nieves
Lucía	Triguero Cueva	Hospital Universitario Virgen de las Nieves
Carlos Javier	Madrid Navarro	Hospital Universitario Virgen de las Nieves
Rosa	Yáñez Baña	Complejo Hospitalario Universitario de Ourense
Asunción	Ávila Rivera	Complex Hospitalari Moisès Broggi
Núria	Caballol Pons	Complex Hospitalari Moisès Broggi
Ana	Planas-Ballvé	Complex Hospitalari Moisès Broggi
Alejandro	Peral Quirós	Complex Hospitalari Moisès Broggi
Dolors	Lozano	Complex Hospitalari Moisès Broggi
Álvaro	Sánchez Ferro	Hospital 12 de Octubre
Pablo	Rábano Suárez	Hospital 12 de Octubre
Antonio	Méndez Guerrero	Hospital 12 de Octubre
Daniel	Pérez Rangel	Hospital 12 de Octubre
Frances	Valldeoriola Serra	Hospital Clínic
Rocío	García Ramos	Hospital Clínico Universitario San Carlos
Ana	Fernández Revuelta	Hospital Clínico Universitario San Carlos
Eva	López Valdés	Hospital Clínico Universitario San Carlos
Carmen	Ribacoba Díaz	Hospital Clínico Universitario San Carlos
Irene	Martínez-Torres	Hospital Universitario la Fe
Carlos	Morata-Martínez	Hospital Universitario la Fe
Raquel	Baviera-Muñoz	Hospital Universitario la Fe
Marina	Campins Romeu	Hospital Universitario la Fe
Isabel	Sastre Bataller	Hospital Universitario la Fe
Pilar	Sánchez Alonso	Hospital Puerta de Hierro
Sabela	Novo Ponte	Hospital Puerta de Hierro
Elisa	Gamo González	Hospital Puerta de Hierro
Raquel	Martín García	Hospital Puerta de Hierro
Pablo	Mir Rivera	Hospital Universitario Virgen del Rocío
Laura	Muñoz Delgado	Hospital Universitario Virgen del Rocío
Astrid Daniela	Adarmes Gómez	Hospital Universitario Virgen del Rocío
Elena	Ojeda Lepe	Hospital Universitario Virgen del Rocío
Silvia	Jesús Maestre	Hospital Universitario Virgen del Rocío

It is made available under a CC-BY 4.0 International license .

Daniel	Macías García	Hospital Universitario Virgen del Rocío
Fátima	Carrillo García	Hospital Universitario Virgen del Rocío
Ana María	Castellano Guerrero***	Hospital Universitario Virgen del Rocío
Manuela	San Eufrasio Martínez***	Hospital Universitario Virgen del Rocío
Cristina	Pérez Calvo***	Hospital Universitario Virgen del Rocío
Andrés	García Herruzo	Hospital Universitario Virgen del Rocío
Cristina	Gómez Rapela*****	Hospital Universitario Virgen del Rocío
Lorena	Garrote Espina*****	Hospital Universitario Virgen del Rocío
Marta	Blázquez Estrada	Hospital Universitario Central de Asturias
Esther	Suárez San Martín	Hospital Universitario Central de Asturias
Ciara	García Fernández	Hospital Universitario Central de Asturias
Patricia	Prendes Fernández****	Hospital Universitario Central de Asturias
Pedro	García Ruíz Espiga	Hospital Fundación Jiménez Díaz
Cici	Feliz Feliz	Hospital Fundación Jiménez Díaz
Raúl	Espinosa Rosso	Hospital Universitario de Jerez
Lara	Mauri Fabrega	Hospital Universitario de Jerez
Jaime	Kulisevsky Bojarski	Hospital Sant Pau de Barcelona
Berta	Pascual Sedano	Hospital Sant Pau de Barcelona
Javier	Pagonabarraga	Hospital Sant Pau de Barcelona
Antonia	Campolongo**	Hospital Sant Pau de Barcelona
Marina	Mata Álvarez-Santullano	Hospital Universitario Infanta Sofía
Juan Carlos	Gómez Esteban	Hospital de Cruces
Tamara	Fernández Valle	Hospital de Cruces
Marta	Ruiz López	Hospital de Cruces
Beatriz	Tijero Merino	Hospital de Cruces
Lydia	López Manzanares	Hospital Universitario La Princesa
Inés	Muro	Hospital Universitario La Princesa
Elena	Casas Peña	Hospital Universitario La Princesa
Pablo	Lorenzo Barreto	Hospital Universitario La Princesa
Maria Pilar	Gil Villar	Hospital Universitari Arnau de Vilanova
Agustín	Sancho Saldana	Hospital Universitari Arnau de Vilanova
Laura	Quibus Requena	Hospital Universitari Arnau de Vilanova
Jesús	Olivares Romero	Hospital Universitario de Torrecárdenas
Belén	Rebollo Lavado	Hospital Universitario de Torrecárdenas
Lucía	Triguero Cueva*	Hospital Universitario de Torrecárdenas
Víctor	Gómez Mayordomo	Hospitales Vithas

It is made available under a CC-BY 4.0 International license .

Berta	Solano Vila	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Anna	Cots Foraster	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Daniel	López Dominguez	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Lilian	Vivas Villacampa	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Jessica	González Ardura	Hospital de Cabueñes
Belén	Castaño García	Hospital de Cabueñes
Antonio	Sánchez Rodríguez	Hospital de Cabueñes
Sonia	Escalante Arroyo	Hospital Virgen de la Cinta
Tania	Delgado Ballestero	Parc Taulí
Débora María	Cerdán Santacruz	Hospital General de Segovia
Amelia	Mendoza Rodríguez	Hospital General de Segovia
Ana	Castrillo Sanz	Hospital General de Segovia
Lorena	Caballero Sánchez	Hospital General de Segovia
Claudia	Gómez López de San Román	Hospital General de Segovia
Gustavo	Fernández Pajarín	Complejo Hospitalario Universitario de Santiago de Compostela
Ángel	Sesar Ignacio	Complejo Hospitalario Universitario de Santiago de Compostela
Jordi	Casanova Mollá	Hospital Universitario Sant Joan de Reus
Ángela	Monterde Ortega	Hospital Universitario Joan XXIII
Susana	Cantarero Duque	Hospital Universitario de Móstoles
Guillermo	González-Ortega	Hospital Universitario de Móstoles
Beatriz	Fernández Rodríguez	Hospital Regional Universitario de Málaga
Teresa	Muñoz Ruíz	Hospital Regional Universitario de Málaga
Gloria	Martí Andrés	Hospital Universitario de Navarra, Pamplona, Navarra
Pedro	Clavero Ibarra	Hospital Universitario de Navarra, Pamplona, Navarra
Amaia	Erdocia Goñi	Hospital Universitario de Navarra, Pamplona, Navarra
Ana Carolina	López Veloso	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Ayoze Nauzet	González Hernández	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Juan Diego	Guerra Hiraldo	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Raúl	Rashid López	Hospital Puerta del Mar, Cádiz
Raúl	Espinosa Rosso	Hospital Puerta del Mar, Cádiz
Silvia	Martí Martínez	Hospital General Universitario Alicante
Ángel	Aneiros Díaz	Complejo Hospitalario Universitario de Ferrol
Lydia	Vela	Hospital Fundación de Alcorcón
Javier	Ruíz Martínez	Hospital Universitario Donostia
Elisabet	Mondragón Rezola	Hospital Universitario Donostia
Ana	Vinagre Aragón	Hospital Universitario Donostia

It is made available under a CC-BY 4.0 International license .

Device-aided therapies in Parkinson's disease

Javier	Gutiérrez García	Complejo Hospitalario Granada
477		

478 The researchers are listed by center in chronological order according to the date they confirmed their participation in

479 the project.

480 * This investigator works at 2 different centers.

481 All investigators are neurologists except those ones with the symbol: ** SN (specialized nurse); ***graduate in Biology

482 (she will be responsible for remote data monitoring); ****neuropsychologist; *****, study coordinator.



Figure